home / stock / alpmf / alpmf articles
Merck & Co Inc (NYSE: MRK) announced that the Phase 3 AMBASSADOR (A031501) trial (KEYNOTE-123) evaluating Keytruda met one of its dual pri...
Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) (OTC: ALPMY) released topline results from the KEYNOTE-A39 Phase...
Astellas Pharma Inc (OTC: ALPMY) (OTC: ALPMF) has elected not to exercise its option to obtain an exclusive license to TSHA-120 unde...
News, Short Squeeze, Breakout and More Instantly...
Merck & Co Inc (NYSE: MRK) announced that the Phase 3 AMBASSADOR (A031501) trial (KEYNOTE-123) evaluating Keytruda met one of its dual pri...
Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) (OTC: ALPMY) released topline results from the KEYNOTE-A39 Phase...
Astellas Pharma Inc (OTC: ALPMY) (OTC: ALPMF) has elected not to exercise its option to obtain an exclusive license to TSHA-120 unde...